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Volunteer unrelated donors, through their extraordinary
altruism, provide a means to perform life-saving hemato-
poietic cell transplantation (HCT) for the approximately 70%
of patients without a suitable family donor. The safety of both
donor and patient is of the utmost concern; consequently,
various processes have been implemented by registries
worldwide to minimize the risk to both parties.
The World Marrow Donor Association has created stan-
dards and an accreditation process for donor registries to
help ensure harmonization among countries and across
continents. Unrelated donors are assessed at various time
points, ranging from registration to the peridonation period
to follow-up long after donation, with the ultimate goal of
optimizing the safety of hematopoietic cell donation from
the perspective of both the donor and the recipient. Although
the risk of donation is quite low, excellent data have char-
acterized the adverse events that occur in association with
the donation process. Moreover, according to reports from
numerous donors, the donation process is a profoundly life-
changing experience. An experience of such signiﬁcance
carries with it the potential for substantial psychological
impact. Here current data addressing both the medical and
psychological impacts of the donation process are reported.
In addition, the use of ﬁlgrastim as a mobilizing agent has
facilitated a dramatic shift toward peripheral blood stem cell
(PBSC) donation as the preferred method for adult patients.
However, concerns have been raised about the long-term
potential effects of ﬁlgrastim on the hematopoietic progen-
itors. Such effects have been studied in laboratory investi-
gations, and the ﬁndings are reviewed here.EARLY AND LATE MEDICAL ISSUES IN STEM CELL
DONATION
Michael A. Pulsipher
Bone marrow (BM) donors undergo blood draws, storage
of autologous units, i.v. line placement, general anesthesia,
and the removal of anywhere from 200 to>1500mL of blood
and marrow in 5- to 10-mL increments from the posterior
iliac crest through large-bore needles placed through 2-4
skin holes and entering the posterior iliac crest from 50 to
more than 200 times on each side. PBSC harvests involve
daily s.c. injections of granulocyte colony-stimulating factor
(G-CSF) for 5þ days, blood draws, i.v. or central lineFinancial disclosure: See Acknowledgment on page S18.
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almost all donors, rarely with more signiﬁcant complica-
tions. Recent studies by various groups have deﬁned the risks
of side effects and complications for each procedure [1-9].
Methods of measuring side effects have varied widely
among studies, however. A recent report from the National
Marrow Donor Program (NMDP) directly compared the
donation experience of BM versus PBSCs for unrelated
donors using Common Terminology Criteria for Adverse
Eventsebased data tools, offering a detailed information for
both donors considering the procedure and for collection
centers [4,10].Comparison of Early BM and PBSC Collection Risks:
Similar Symptoms, Different Timing
Although BM and PBSC collection procedures differ
greatly (anesthesia and BM manipulation versus G-CSF
therapy and apheresis), the main symptoms experienced by
BM and PBSC donors were similar: pain, fatigue, insomnia,
local reactions (eg, i.v. placement issues, inﬁltration, G-CSF
injection), dizziness, anorexia, emesis, rash, and occasional
fever or syncope. Figure 1 compares the location and degree
of pain, and Figure 2 compares the degree of speciﬁc symp-
toms experienced by BM and PBSC donors at the peak of
symptoms (day þ5 of G-CSF therapy immediately before
apheresis for PBSC donors and 1-2 days after collection for
BM donors).
Nearly 90% of all donors experienced pain, mostly mild,
with approximately 20% experiencing moderate pain and
a small percentage severe or disabling pain. The main
pain sites in BM donors were the back (site of harvest) and
throat (intubation site); PBSC donation pain (from G-CSF)
was commonly reported in multiple sites (back, hip,
limbs, joints). Headache has been reported as well. Fatigue
and insomnia are among the most common nonpain symp-
toms experienced by both BM and PBSC donors, with more
fatigue after BM donation and more insomnia after PBSC
donation [10].
The main difference in symptoms experienced after the 2
donation procedures is in the timing in relation to each
donation procedure and the time to full recovery. In PBSC
donors, discomfort begins as early as day þ2 of G-CSF
administration, within 24 hours of receiving the ﬁrst G-CSF
dose. Symptoms peak at days þ4 to þ5 of G-CSF before the
collection procedure begins. New symptoms can occur
during the apheresis procedure (eg, line placement issues,
hypocalcemia), followed by a decrease in symptoms after the
ﬁrst apheresis and a marked drop within 24-48 hours of
stopping G-CSF.Transplantation.
Figure 1. Location and degree of pain reported within 2 days of collection in BM donors (A) and on day þ5 of G-CSF therapy in PBSC donors (B). (Reprinted with
permission [10].)
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other symptoms begin during and directly after the harvest.
Immediate symptoms can occur as a result of anesthesia and
intubation (eg, sore throat, nausea). Many donors experience
delayed pain owing to local anesthesia and more intense
pain medications (eg, i.v. narcotics) given early post-
operatively, resulting in peaks in pain and constitutional
symptoms at 24-48 hours after collection, with a slow
decline over the ﬁrst week and mild pain lingering for up to
several weeks in some donors. Figure 3 shows that full
recovery after BM collection is somewhat delayed compared
with that after PBSC collection. This ﬁnding is partially offset
by the fact that pain during PBSC collection starts earlier;
however, even with this, a small percentage of BM donors
experience lingering symptoms that persist for months,
whereas PBSC donors almost invariably report full recovery.
Although full recovery is slower in BM donors compared
with PBSC donors, the persistent symptoms are almost all
grade 1 (mild) pain or toxicities. By 1 week after collection,
<1% of both BM and PBSC donors reported grade 3 pain or
toxicities, 11% of BM donors and 1% of PBSC donors reported
grade 2 (moderate) pain, and 6% of BM donors and 2% of PBSC
donors reported at least 1 grade 2 toxicity. At 1 month
follow-up, fewer than 1% of all donors reported non-pain
toxicities; 2 and 1% of BM and PBSC donors respectively re-
ported grade 2 pain. In PBSC donors, all toxicity and pain
measures returned to baseline values by 1 month. The
primary difference between BM and PBSC donors at 1 month
was in the rate of grade 1 (mild) pain, 11% in BM donors and
3% in PBSC donors (baseline values, 4%-5%) [10].
Previous studies have deﬁned speciﬁc differences in the
risk of side effects in certain groups. For example, donors
who are overweight or obese tend to have a higher incidence
of moderate to severe pain with PBSC donation [1]. PBSCFigure 2. Rates of speciﬁc symptoms and the intensity of those symptoms experience
in PBSC donors (B). (Reprinted with permission [10].)donors of any size are more likely to experience more severe
pain, but only a very low percentage (<2%) of donors actu-
ally do experience this level of pain. In addition, women are
more likely than men to experience pain, toxicities, and
fatigue during the pericollection period and at 1 week and 1
month later regardless of the type of collection they have
undergone. Age at donation has an unusual impact; older
donors have a lower likelihood of pain in the early collection
period, but a higher risk of persistent pain at 1 week post-
donation. Although older donors have a similar risk of
experiencing toxicities in the pericollection period as
younger donors, they have a much greater risk of reporting
persistent toxicities and fatigue at 1 week, reﬂecting
a slower recovery period compared with younger donors for
all aspects of the donation process. Women are almost
twice as likely as men to require extended hospitalization
(P ¼ .028). For PBSC collection, women are more likely to
require a central venous catheter (21% versus 5%; P < .001)
and to experience apheresis-related adverse events
(P < .001) [11].
Severe Adverse Events and Late Risks: BM versus PBSCs
A major challenge in understanding rates of severe
adverse events (SAEs) after BM or PBSC donation is the wide
variation in deﬁnitions of SAE in studies reported to date.
With that in mind, most studies have reported rates of 1% or
less [11-13], with exceptionally low mortality (risk, approx-
imately 1 in 10,000) [13]. To make reporting as reﬁned as
possible, the NMDP recently reviewed all reported adverse
events from a cohort of 2728 BM donors and 6768 PBSC
donors who donated between 2004 and 2009. SAEs had to
meet one of the US Food and Drug Administration’s deﬁni-
tions of SAE: death, unexpected or prolonged hospitaliza-
tion, persistent signiﬁcant disability, congenital anomaly, ord within 2 days of collection in BM donors (A) and on day þ5 of G-CSF therapy
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Figure 3. Time to report of complete recovery, BM versus PBSCs. (Reprinted
with permission [10].)
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In the NMDP analysis, when all events by these deﬁnitions
were considered, SAE rates appeared to be signiﬁcantly
elevated after BM harvest, owing mainly to unexpected
hospitalizations for common events after collection (eg,
fainting, pain, dehydration), occurring in 1.6% of men and
3.6% of women. Because planned and unplanned hospitali-
zation rates vary, further analysis was performed removing
unplanned hospitalization related to common or expected
events. Overall rates of SAEs were lower and consistent with
more traditional reports (<1%), but remained somewhat
elevated in BM donors compared with PBSC donors
(M. Pulsipher, unpublished data). The 3 main types of SAEs
included life-threatening events (eg, pulmonary embolus),
overnight hospitalization for unexpected events, and
persistent or signiﬁcant disability (mostly mild chronic pain,
especially after BM donation).
Although concerns have been raised regarding the theo-
retical possibility that G-CSF use by donors could increase
rates of cancer, thrombosis, and new onset or ﬂares of
autoimmune illnesses after donation, in this cohort of nearly
10,000 patients, no differences in the rates of any of these
conditions were noted between BM and PBSC donors in the
years after donation.
Conclusion
BM and PBSC donation is generally considered safe;
however, the 2 procedures have differences in timing of
onset of adverse events, degrees of discomfort, and recovery
proﬁles. In addition, donor age, sex, andweight affect toxicity
proﬁles for early events, but not for SAEs. Late toxicities of
thrombosis, autoimmune illness, or cancer appear to be
similar in BM and PBSC donors, suggesting that G-CSF does
not increase the risk of these events.
PSYCHOSOCIAL ISSUES IN STEM CELL DONATION
Galen E. Switzer
In recent years, HCT has become an increasingly popular
treatment option for persons with leukemia and other
blood-related diseases. Because only a minority of patients
requiring HCTcan ﬁnd a HLA-matched related hematopoietic
stem cell (HSC) donor, approximately 14,000 patients each
year search international registries for a suitable unrelated
donor. The longitudinal trajectory for unrelated HSC donors
begins with joining a donor registry, continues as donors areidentiﬁed and tested for HLA matching with a patient, and
culminates in actual donation. Across this trajectory,
multiple factors that may affect or be affected by donor
psychosocial issues.
Race/Ethnicity and Psychosocial Issues at Conﬁrmatory
Typing
A critical decision point for potential donors leading to
actual donation is conﬁrmatory typing (CT). Registry
members identiﬁed as a potential match for a patient are
contacted at CT to undergo blood tests and receive detailed
information about their role as a potential donor. At this
decision point, whites are approximately 30% more likely to
agree to move forward toward donation compared with all
other racial/ethnic groups. This difference in attrition at CT
stage has remained relatively constant throughout the past
2-1/2 decades. Although it is clear that the whiteeminority
difference in attrition likely has little to do with simple
membership in a minority group, factors that might be
associated both with racial/ethnic group and the risk of
opting out of the registry were not fully investigated.
Previous investigations conducted primarily with white
potential donors found that higher donor ambivalence (ie,
doubts and worries about donation) is strongly associated
with the decision to opt out of the registry at CT [14].
Whether ambivalence or other culturally related factors
function differently by racial/ethnic group in the CT decision
was unknown. We recently completed an investigation
examining factors potentially associated both with race/
ethnicity and attrition from the registry above and beyond
donor demographic characteristics. We identiﬁed 3 classes
of variablesdculturally related, psychosocial, and donation-
relateddthat have been associated either with race/
ethnicity or with the decision to opt out of the registry. Our
investigation examined whether associations between these
factors and attrition would provide insight into the greater
minority group attrition at this key decision point leading to
donation.
Potential donors were contacted and interviewed after
preliminarymatching with a patient in need of HCT, at which
point they decided either to continue toward donation or to
opt out of the registry. The sample was stratiﬁed by race and
CT decision (continue or opt out) and included 843 potential
donors: 28% white, 19% African American, 25% Hispanic, 21%
Asian/Paciﬁc Islander, and 7% American Indian. Analyses
examined differences in key variables by race/ethnicity and
factors associated with attrition.
Findings suggest that four factors are especially important
both in terms of their association with minority group
membership and their association with increased risk of
attrition. Compared with whites, minorities reported more
religious objections to donation (African American, Hispanic,
Asian/Paciﬁc Islander, American Indian), less trust that HSCs
would be allocated equitably (African American, Asian/
Paciﬁc Islander), more concerns about donation (Hispanic,
Asian/Paciﬁc Islander), and a greater likelihood of being
discouraged from donating (Asian/Paciﬁc Islander).
Findings from multivariate analyses within racial/ethnic
groups were informative as well. Ambivalence emerged in
the multivariate analyses as to the factor most strongly
associated with attrition regardless of group membership.
The fact that ambivalence was so strongly associated with
attrition but not with racial/ethnic group membership
implies that this is a critical and universal factor in the
decision of whether or not to proceed toward donation.
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Evidence indicates that both BM and PBSC donation are
safe with a low incidence of adverse events [1,15,16]. Thus,
the decision about which product will be donated is left to
the transplant physician managing the patient. The use of
PBSC donation has steadily increased in recent years, and
PBSCs now account for 75% of all unrelated adult donations
[17]. However, there is no evidence that the donation of 1
product or the other results in a survival advantage for
patients. Neither is there conclusive evidence regarding the
relative health-related quality-of-life costs and beneﬁts to
donors themselves.
To address questions about the relative advantages/
disadvantages to both patients and donors of the 2 HSC
collection procedures, the Blood and Marrow Transplant
Clinical Trials Network (BMT-CTN) recently completed
a phase III trial randomizing patients to receive either
marrow or PBSCs. Our investigation was a prespeciﬁed
subgroup analysis of BMT-CTN protocol 0201. The prospec-
tive, longitudinal investigation included NMDP donors who
were enrolled in the parent randomized controlled trial and
randomized to donate PBSCs or BM. Donors were inter-
viewed before donation and at 48 hours, 6 months, and 12
months after donation.
Four broad categories of participant characteristics were
assessed in the interview: (1) sociodemographic, (2) physical
status, (3) psychosocial status, and (4) donation-related.
Speciﬁc factors within each broad category represented
conceptual subcomponents of the broader category.
Comparing the 2 types of donors revealed similarities in key
study variables before donation, although BM donors
expressed feeling more prepared for donation compared
with PBSC donors. Shortly after donation, BM donors re-
ported higher levels of multiple symptoms and a greater
impact of donation on social activities. There were virtually
no differences between the 2 groups on key study variables
at 6 and 12 months postdonation and no difference in the
rate at which donors recovered from donation.
HEALTHY PBSC DONORS, G-CSF, AND CHROMOSOMES
Willis H. Navarro
NMDP data indicate that PBSCs overtook BM in 2003 as
the most popular source for hematopoietic reconstitution in
the setting of allogeneic HCT [17]. Despite widespread
adoption of PBSC collection from healthy unrelated donors,
concerns have been raised regarding long-term genotoxic
effects of short-duration G-CSF exposure [3,18-23]. To date,
epidemiologic data have not suggested any clinically relevant
increase in leukemia risk [1,3,18,20,22,24]; however, such
studies have been limited by the rarity of hematopoietic
malignancies in general and by the statistical limitations
imposed by even the substantial number of donors included
in studies examining this issue. A recent study conducted in
12,559 healthy PBSC donors in Germany failed to show any
predilection toward acute leukemia in the donors studied
[24]; however, the limited statistical power of the study
allowed only for the exclusion of a 3-fold increase in the risk
of acute myeloid leukemia.
Regarding genomic changes, Nagler et al. [25] published
the results of their study of G-CSF exposure on the genetics
and epigenetics in the lymphocytes of normal hematopoietic
cell donors, showing that the lymphocytes displayed both
epigenetic and genetic changes. The investigators noted that
donor lymphocytes demonstrated allele-speciﬁc asynchrony
as manifest by the presence of singlet/doublet signals whenexamining TP53, AML1, and CEN17 by FISH at a rate much
higher than controls and similar to samples derived from
patients with hematologic malignancies. Nagler et al. [25]
also reported increased aneuploidy by FISH at chromosome
17 using a CEN17 probe in G-CSFetreated healthy donor
lymphocytes compared with normal controls but similar to
those from patients with hematologic malignancy. Exami-
nation of samples from donors at about 3.5 months after
donation showed that the epigenetic changes (allele-speciﬁc
asynchrony) had resolved, but aneuploidy remained higher
than in controls. In contradistinction, in 2011 Hirsch et al.
[26] reported a similar study showing no evidence of G-CSFe
induced aneuploidy or replication asynchrony. There were
some important differences in techniques between the
Nagler et al. and Hirsch et al. investigations. Nagler et al.
assessed aneuploidy via FISH, querying only the CEN17
locus at chromosome 17. Hirsch et al. also used FISH, but
used 9 probes: three for chromosome 7; one each for
genes on chromosomes 8, 9, 21, and 22; and two for chro-
mosome 17, including CEN17 as used by Nagler et al. Cells
were prepared either with phytohemagglutinin (PHA) stim-
ulation in accordance with the technique of Nagler et al. or
without PHA stimulation, to assess impact on aneuploidy.
G-CSFeexposed lymphocytes showed no statistically signif-
icant differences in aneuploidy compared with controls for
any of the probes. Of note, the CEN17 probe demonstrated
the highest level of aneuploidy for both controls and
G-CSFeexposed cells.
A third study using healthy G-CSFemobilized unrelated
donors was recently published by Marmier-Savet et al. [27]
showing increased aneuploidy by FISH only in the CD34
PBSC product fraction obtained via positive selection for
CD34þ using immunomagnetic sorting. Aneuploidy levels
were assessed using centromeric probes for chromosomes 8
and 17. Aneuploidy in the CD34- fraction gradually returned
to baseline after 1 year. The CD34þ fraction from the mobi-
lized product showed no increase in aneuploidy at any time
point.
To address these concerns, the NMDP is conducting
a long-term donor follow-up study (NCT 01362179) speciﬁ-
cally aimed at tracking the incidence of malignancies,
including hematologic cancers, as well as thrombosis and
autoimmunity. Because of the lengthy follow-up and the
large number of donors required, the study is expected to
enroll more than 32,000 donors through 2014, with follow-
up through 2019 and ﬁnal analysis in 2020.
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